Table 1 Bivariate analysis of risk factors affecting the duration of hospitalization among the recovered COVID-19 patients
Length of stay (recovered) | p-value | ||
|---|---|---|---|
Median | (Min–max) | ||
Age | |||
< 18 | 23 | (10–42) | < 0.001*a |
18–35 | 20 | (10–40) | |
35–55 | 15 | (10–35) | |
> 55 | 21 | (20–22) | |
Sex | |||
Male | 22 | (10–40) | 0.125b |
Female | 20 | (10–42) | |
Smoking | |||
Yes | 22 | (10–38) | 0.109b |
No | 22 | (10–42) | |
Fever | |||
Yes | 22 | (10–42) | 0.478b |
No | 22 | (10–41) | |
Cough | |||
Yes | 22 | (10–42) | 0.005*b |
No | 20 | (10–35) | |
Headache | |||
Yes | 22 | (10–42) | 0.578b |
No | 22 | (10–41) | |
Malaise | |||
Yes | 21 | (10–42) | 0.017*b |
No | 22 | (10–42) | |
Dyspnea | |||
Yes | 22 | (10–42) | 0.007*b |
No | 21 | (10–41) | |
Vomiting | |||
Yes | 22 | (10–41) | 0.707b |
No | 22 | (10–42) | |
Loss of taste and smell | |||
Yes | 20 | (10–40) | 0.0631b |
No | 22 | (10–42) | |
Hypertension | |||
Yes | 22 | (10–41) | < 0.001*b |
No | 20 | (10–42) | |
Diabetes | |||
Yes | 24 | (10–42) | < 0.001*b |
No | 20 | (10–38) | |
Asthma | |||
Yes | 20 | (10–41) | 0.289b |
No | 22 | (10–42) | |
Sore throat | |||
Yes | 22 | (10–42) | 0.94b |
No | 22 | (10–42) | |
Pulmonary embolism | |||
Yes | 24 | (10–41) | 0.015*b |
No | 20 | (10–38) | |
Lymphocytic level | |||
Lymphopenia | 22 | (10–42) | < 0.001*a |
Normal | 20 | (10–40) | |
Lymphocytosis | 16 | (10–34) | |
C-reactive protein level | |||
< 5 | 17 | (10–37) | < 0.001*a |
5–100 | 20 | (10–40) | |
100–200 | 25 | (12–42) | |
200–300 | 30 | (10–38) | |
> 300 | 33 | (15–41) | |
CO-RAD scale | |||
Rad 1–2 | 14.5 | (10–30) | < 0.001*a |
Rad 3 | 17 | (10–32) | |
Rad 4 | 22 | (10–42) | |
Rad 5–6 | 28 | (15–41) | |
Viral load | |||
High | 28 | (10–42) | < 0.001*a |
Intermediate | 22 | (10–38) | |
Low | 14 | (10–25) | |